---
created: 2025-04-13
updated: 2025-04-13T10:53
id: gPfv2.3|,h
specialty: pharmaco
specialty_id: 542
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::09-cancer-therapy-cell-cycle
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::26-palbociclib
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::smallmoleculeinhibitors(tyrosinekinase-proteasomeinhibitors-cdkinhibitors)
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::15000-15999::15299
  - source/ak-step1-v11::^other::^expn::bgadd
  - source/ak-step1-v11::^other::^fa-updates::fa2018
  - source/ak-step1-v11::^other::^highyield::4-loweryield"
type: flashcard
---

# Question
The major side effect of Palbociclib is **neutropenia**; tx of breast CA through inhibition of CDKs 4 'n' 6, which normally regulate cell progression from phase G1 to S

---

# Answer
also leukopenia, anemia, thrombocytopenia, ie. bone marrow suppression   secondarily, respiratory infection & pulmonary embolism